Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway

Experimental Hematology

Volumn 38, Issue 6, 2010, Pages 472-480

  Lu, Min ^a   Zhang, Wei ^a   Li, Yan ^a   Berenzon, Dmitriy ^a   Wang, Xiaoli ^a   Wang, Jiapeng ^a   Mascarenhas, John ^a,b   Xu, Mingjiang ^a,b   Hoffman, Ronald ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Myeloproliferative Disorder Research Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; CD34 ANTIGEN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

APOPTOSIS; ARTICLE; BURST FORMING UNIT E; CD34 SELECTION; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ERYTHROID CELL; GROWTH INHIBITION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIGENS, CD34; BLOTTING, WESTERN; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION;

EID: 77952955507     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.03.005     Document Type: Article

References (49)

1. James C., Ugo V., Le Couédic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
2. Kralovics R., Teo S.S., Buser A.S., et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005, 106:3374-3376.
3. Levine R.L., Gilliland D.G. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 2007, 14:43-47.
4. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
5. James C., Ugo V., Casadevall N., Constantinescu S.N., Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005, 11:546-554.
6. Silver R.T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006, 107:451-458.
7. Gilbert H.S. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998, 83:1205-1213.
8. Liu E., Jelinek J., Pastore Y.D., et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003, 101:3294-3301.
9. Massaro P., Foa P., Pomati M., et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol 1997, 56:126-128.
10. Messora C., Bensi L., Vecchi A., et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 1994, 86:402-404.
11. Chott A., Gisslinger H., Thiele J., et al. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1990, 74:10-16.
12. Bellucci S., Harousseau J.L., Brice P., Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988, 2:960-961.
13. Giles F.J., Singer C.R., Gray A.G., et al. Alpha-interferon therapy for essential thrombocythaemia. Lancet 1988, 2:70-72.
14. Sacchi S., Leoni P., Liberati M., et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 1994, 68:247-250.
15. Radin A.I., Kim H.T., Grant B.W., et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 2003, 98:100-109.
16. Lengfelder E., Berger U., Hehlmann R. Interferon alfa in the treatment of polycythemia vera. Ann Hematol 2000, 79:103-109.
17. Chevaliez S., Pawlotsky J.M. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007, 59:1222-1241.
18. Grace M.J., Cutler D.L., Bordens R.W. Pegylated IFNs for chronic hepatitis C: an update. Expert Opin Drug Deliv 2005, 2:219-226.
19. Alvarado Y., Cortes J., Verstovsek S., et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003, 51:81-86.
20. Kiladjian J.J., Cassinat B., Turlure P., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006, 108:2037-2040.
21. Kiladjian J.J., Cassinat B., Chevret S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
22. Samuelsson J., Hasselbalch H., Bruserud O., et al. Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006, 106:2397-2405.
23. Jabbour E., Kantarjian H., Cortes J., et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007, 110:2012-2018.
24. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 2003, 98:129-142.
25. Goh K.C., Haque S.J., Williams B.R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999, 18:5601-5608.
26. Uddin S., Lekmine F., Sharma N., Majchrzak B., et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000, 275:27634-27640.
27. Mayer I.A., Verma A., Grumbach I.M., et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001, 276:28570-28577.
28. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
29. Ishii T., Bruno E., Hoffman R., Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006, 108:3128-3134.
30. Ishii T., Xu M., Zhao Y., Hu W.Y., Ciurea S., Bruno E., Hoffman R. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Leukemia 2007, 21:373-374.
31. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007, 282:20047-20051.
32. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu Rev Biochem 1987, 56:727-777.
33. Biron C.A. Role of early cytokines, including α and β interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin Immunol 1998, 10:383-390.
34. Carlo-Stella C., Cazzola M., Gasner A., et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987, 70:1014-1019.
35. Castello G., Lerza R., Cerruti A., et al. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 1994, 87:621-623.
36. Wang Q., Miyakawa Y., Fox N., Kaushansky K., et al. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000, 96:2093-2099.
37. Sato T., Yoshihara N.O.H., Suda F.A.T., Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 2009, 15:696-700.
38. Essers M.A., Offner S., Blanco-Bose W.E., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
39. Grace M.J., Lee S., Bradshaw S., et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 2005, 280. 6327-6236.
40. Larsen T.S., Bjerrum O.W., Pallisgaard N., et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008, 87:847-850.
41. Brassard D., Bradshaw S., Chapman J., et al. Differential responsiveness of interferon α 2 signaling by pagylated interferon α 2b and pagylated interferon a 2a. Hepatology 2002, 36:548A.
42. Jones A.V., Silver R.T., Waghorn K., et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006, 107:3339-3341.
43. Cox S., Youngster S., Leaman D., et al. Pegylated interferon α 2b and pegylated interferon α 2a. Hepatology exhibit different anti-viral activity in vitro. Hepatology 2002, 36:547A.
44. Leaman D., Brassard D., Cox S., et al. Pagylated interferon α 2b and pagylated interferon α 2a. Hepatology exhibit different anti-proliferative activity in vitro. Hepatology 2002, 36:547A.
45. Samuelsson J., Mutschler M., Birgegård G., et al. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006, 91:1281-1282.
46. Xiong Z., Liu E., Yan Y., Silver R.T., et al. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol 2006, 177:4907-4916.
47. Xiong Z., Yan Y., Liu E., et al. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol 2007, 122:279-287.
48. Milhem M., Mahmud N., Lavelle D., et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood 2004, 103:4102-4110.
49. Alsayed Y., Uddin S., Mahmud N., et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001, 276:4012-4019.